-
1
-
-
29344457180
-
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
-
Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006, 47:e1-e121.
-
(2006)
J Am Coll Cardiol
, vol.47
-
-
Smith, S.C.1
Feldman, T.E.2
Hirshfeld, J.W.3
-
2
-
-
0035912690
-
ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions
-
Smith S.C., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001, 103:3019-3041.
-
(2001)
Circulation
, vol.103
, pp. 3019-3041
-
-
Smith, S.C.1
Dove, J.T.2
Jacobs, A.K.3
-
4
-
-
0034622539
-
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
-
Bertrand M.E., Rupprecht H.J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000, 102:624-629.
-
(2000)
Circulation
, vol.102
, pp. 624-629
-
-
Bertrand, M.E.1
Rupprecht, H.J.2
Urban, P.3
-
5
-
-
70450199115
-
2009 Focused Updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guide
-
Kushner F.G., Hand M., Smith S.C., et al. 2009 Focused Updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 2205-2241
-
-
Kushner, F.G.1
Hand, M.2
Smith, S.C.3
-
6
-
-
38049183243
-
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008, 117:296-329.
-
(2008)
Circulation
, vol.117
, pp. 296-329
-
-
Antman, E.M.1
Hand, M.2
Armstrong, P.W.3
-
7
-
-
38049169354
-
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008, 117:261-295.
-
(2008)
Circulation
, vol.117
, pp. 261-295
-
-
King, S.B.1
Smith, S.C.2
Hirshfeld, J.W.3
-
8
-
-
33646732608
-
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
-
Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27:1166-1173.
-
(2006)
Eur Heart J
, vol.27
, pp. 1166-1173
-
-
Jernberg, T.1
Payne, C.D.2
Winters, K.J.3
-
9
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
-
(2009)
N Engl J Med
, vol.360
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
10
-
-
77953911457
-
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
-
Working Group on High On-Treatment Platelet Reactivity
-
Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933. Working Group on High On-Treatment Platelet Reactivity.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 919-933
-
-
Bonello, L.1
Tantry, U.S.2
Marcucci, R.3
-
11
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
-
(2007)
N Engl J Med
, vol.357
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
12
-
-
33748680917
-
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
-
TRITON-TIMI 38 Investigators
-
Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006, 152:627-635. TRITON-TIMI 38 Investigators.
-
(2006)
Am Heart J
, vol.152
, pp. 627-635
-
-
Wiviott, S.D.1
Antman, E.M.2
Gibson, C.M.3
-
13
-
-
34249657466
-
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians
-
Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007, 138:652-655.
-
(2007)
J Am Dent Assoc
, vol.138
, pp. 652-655
-
-
Grines, C.L.1
Bonow, R.O.2
Casey, D.E.3
-
14
-
-
19644372173
-
Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
-
Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111:2560-2564.
-
(2005)
Circulation
, vol.111
, pp. 2560-2564
-
-
Hochholzer, W.1
Trenk, D.2
Frundi, D.3
-
15
-
-
77955492857
-
-
Bristol-Myers Squibb Sanofi-aventis, Bridgewater, NJ, Sanofi-aventis
-
Plavix (clopidogrel bisulfate) [package insert] 2010, Bristol-Myers Squibb Sanofi-aventis, Bridgewater, NJ, Sanofi-aventis.
-
(2010)
Plavix (clopidogrel bisulfate) [package insert]
-
-
-
16
-
-
54449095374
-
Clopidogrel use and bleeding after coronary artery bypass graft surgery
-
Kim J.H., Newby L.K., Clare R.M., et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008, 156:886-892.
-
(2008)
Am Heart J
, vol.156
, pp. 886-892
-
-
Kim, J.H.1
Newby, L.K.2
Clare, R.M.3
-
17
-
-
34249053105
-
The disposition of prasugrel, a novel thienopyridine, in humans
-
Farid N.A., Smith R.L., Gillespie T.A., et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007, 35:1096-1104.
-
(2007)
Drug Metab Dispos
, vol.35
, pp. 1096-1104
-
-
Farid, N.A.1
Smith, R.L.2
Gillespie, T.A.3
-
18
-
-
33645105318
-
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
-
Rehmel J.L., Eckstein J.A., Farid N.A., et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006, 34:600-607.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 600-607
-
-
Rehmel, J.L.1
Eckstein, J.A.2
Farid, N.A.3
-
19
-
-
79957660790
-
-
Eli Lilly and Company, Indianapolis, Ind
-
Effient (prasugrel) [package insert] 2010, Eli Lilly and Company, Indianapolis, Ind.
-
(2010)
Effient (prasugrel) [package insert]
-
-
-
20
-
-
68649094164
-
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
-
Small D.S., Farid N.A., Li Y.G., et al. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. J Clin Pharm Ther 2009, 34:575-583.
-
(2009)
J Clin Pharm Ther
, vol.34
, pp. 575-583
-
-
Small, D.S.1
Farid, N.A.2
Li, Y.G.3
-
21
-
-
34447271701
-
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status
-
Weerakkody G.J., Jakubowski J.A., Brandt J.T., et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007, 100:331-336.
-
(2007)
Am J Cardiol
, vol.100
, pp. 331-336
-
-
Weerakkody, G.J.1
Jakubowski, J.A.2
Brandt, J.T.3
-
22
-
-
36348977461
-
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
-
Payne C.D., Li Y.G., Small D.S., et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007, 50:555-562.
-
(2007)
J Cardiovasc Pharmacol
, vol.50
, pp. 555-562
-
-
Payne, C.D.1
Li, Y.G.2
Small, D.S.3
-
23
-
-
79952355781
-
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability
-
Ancrenaz V., Daali Y., Fontana P., et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010, 11:667-677.
-
(2010)
Curr Drug Metab
, vol.11
, pp. 667-677
-
-
Ancrenaz, V.1
Daali, Y.2
Fontana, P.3
-
24
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
-
(2009)
JAMA
, vol.302
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
-
25
-
-
67649645191
-
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
-
Varenhorst C., James S., Erlinge D., et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009, 30:1744-1752.
-
(2009)
Eur Heart J
, vol.30
, pp. 1744-1752
-
-
Varenhorst, C.1
James, S.2
Erlinge, D.3
-
26
-
-
77958567291
-
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data
-
Sorich M.J., Vitry A., Ward M.B., et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010, 8:1678-1684.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 1678-1684
-
-
Sorich, M.J.1
Vitry, A.2
Ward, M.B.3
-
27
-
-
37349103200
-
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
-
Farid N.A., Payne C.D., Ernest C.S., et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008, 48:53-59.
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 53-59
-
-
Farid, N.A.1
Payne, C.D.2
Ernest, C.S.3
-
28
-
-
57149084688
-
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects
-
Farid N.A., Small D.S., Payne C.D., et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008, 28:1483-1494.
-
(2008)
Pharmacotherapy
, vol.28
, pp. 1483-1494
-
-
Farid, N.A.1
Small, D.S.2
Payne, C.D.3
-
29
-
-
34247256797
-
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
-
Farid N.A., Payne C.D., Small D.S., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007, 81:735-741.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 735-741
-
-
Farid, N.A.1
Payne, C.D.2
Small, D.S.3
-
30
-
-
67650844202
-
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects
-
Farid N.A., Jakubowski J.A., Payne C.D., et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009, 25:1821-1829.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 1821-1829
-
-
Farid, N.A.1
Jakubowski, J.A.2
Payne, C.D.3
-
31
-
-
40749094082
-
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
-
Small D.S., Farid N.A., Payne C.D., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475-484.
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 475-484
-
-
Small, D.S.1
Farid, N.A.2
Payne, C.D.3
-
32
-
-
50249184573
-
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
-
Small D.S., Farid N.A., Li Y.G., et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008, 24:2251-2257.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 2251-2257
-
-
Small, D.S.1
Farid, N.A.2
Li, Y.G.3
-
34
-
-
77953896604
-
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
-
Hulot J.S., Collet J.P., Silvain J., et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010, 56:134-143.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 134-143
-
-
Hulot, J.S.1
Collet, J.P.2
Silvain, J.3
-
35
-
-
36348943475
-
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
-
Brandt J.T., Close S.L., Iturria S.J., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007, 5:2429-2436.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2429-2436
-
-
Brandt, J.T.1
Close, S.L.2
Iturria, S.J.3
-
36
-
-
77649332028
-
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial
-
Small D.S., Payne C.D., Kothare P., et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 2010, 32:365-379.
-
(2010)
Clin Ther
, vol.32
, pp. 365-379
-
-
Small, D.S.1
Payne, C.D.2
Kothare, P.3
-
37
-
-
76949099975
-
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
-
Small D.S., Kothare P., Yuen E., et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010, 66:127-135.
-
(2010)
Eur J Clin Pharmacol
, vol.66
, pp. 127-135
-
-
Small, D.S.1
Kothare, P.2
Yuen, E.3
-
38
-
-
77955618350
-
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial
-
Ge J., Zhu J., Hong B.K., et al. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Curr Med Res Opin 2010, 26:2077-2085.
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 2077-2085
-
-
Ge, J.1
Zhu, J.2
Hong, B.K.3
-
39
-
-
61549124132
-
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
-
Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
-
(2009)
JAMA
, vol.301
, pp. 937-944
-
-
Ho, P.M.1
Maddox, T.M.2
Wang, L.3
-
40
-
-
78149487926
-
Clopidogrel with or without omeprazole in coronary artery disease
-
COGENT Investigators
-
Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917. COGENT Investigators.
-
(2010)
N Engl J Med
, vol.363
, pp. 1909-1917
-
-
Bhatt, D.L.1
Cryer, B.L.2
Contant, C.F.3
-
41
-
-
84856618024
-
-
U.S. Food and Drug Administration, February 3, 2009, Accessed January 5, 2011
-
Cardiovascular and Renal Drug Advisory Committee Briefing Document U.S. Food and Drug Administration, February 3, 2009, Accessed January 5, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm129219.pdf.
-
Cardiovascular and Renal Drug Advisory Committee Briefing Document
-
-
-
42
-
-
37349111065
-
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
-
PRINCIPLE-TIMI 44 Investigators
-
Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923-2932. PRINCIPLE-TIMI 44 Investigators.
-
(2007)
Circulation
, vol.116
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
-
43
-
-
21644448736
-
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
-
Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005, 111:3366-3373.
-
(2005)
Circulation
, vol.111
, pp. 3366-3373
-
-
Wiviott, S.D.1
Antman, E.M.2
Winters, K.J.3
-
45
-
-
54149097794
-
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
-
Murphy S.A., Antman E.M., Wiviott S.D., et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008, 29:2473-2479.
-
(2008)
Eur Heart J
, vol.29
, pp. 2473-2479
-
-
Murphy, S.A.1
Antman, E.M.2
Wiviott, S.D.3
-
46
-
-
60649112469
-
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
-
Montalescot G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731.
-
(2009)
Lancet
, vol.373
, pp. 723-731
-
-
Montalescot, G.1
Wiviott, S.D.2
Braunwald, E.3
-
47
-
-
55949103494
-
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38
-
Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
-
(2008)
Circulation
, vol.118
, pp. 1626-1636
-
-
Wiviott, S.D.1
Braunwald, E.2
Angiolillo, D.J.3
-
48
-
-
68949183521
-
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy
-
Pride Y.B., Wiviott S.D., Buros J.L., et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J 2009, 158:e21-e26.
-
(2009)
Am Heart J
, vol.158
-
-
Pride, Y.B.1
Wiviott, S.D.2
Buros, J.L.3
-
49
-
-
42149119040
-
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
-
TRITON-TIMI 38 Investigators
-
Wiviott S.D., Braunwald E., McCabe C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008, 371:1353-1363. TRITON-TIMI 38 Investigators.
-
(2008)
Lancet
, vol.371
, pp. 1353-1363
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
50
-
-
43749117048
-
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis
-
Antman E.M., Wiviott S.D., Murphy S.A., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008, 51:2028-2033.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 2028-2033
-
-
Antman, E.M.1
Wiviott, S.D.2
Murphy, S.A.3
-
51
-
-
74249088972
-
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study
-
Montalescot G., Sideris G., Cohen R., et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010, 103:213-223.
-
(2010)
Thromb Haemost
, vol.103
, pp. 213-223
-
-
Montalescot, G.1
Sideris, G.2
Cohen, R.3
-
52
-
-
77956681628
-
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study
-
SWAP Investigators
-
Angiolillo D.J., Saucedo J.F., Deraad R., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010, 56:1017-1023. SWAP Investigators.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 1017-1023
-
-
Angiolillo, D.J.1
Saucedo, J.F.2
Deraad, R.3
-
53
-
-
0025851456
-
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial
-
Bovill E.G., Terrin M.L., Stump D.C., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991, 115:256-265.
-
(1991)
Ann Intern Med
, vol.115
, pp. 256-265
-
-
Bovill, E.G.1
Terrin, M.L.2
Stump, D.C.3
-
54
-
-
79957668478
-
-
FDA Advisory Committee Docket, Accessed December 29, 2010
-
FDA Advisory Committee Docket, Accessed December 29, 2010. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf.
-
-
-
-
55
-
-
36548998846
-
Universal definition of myocardial infarction
-
Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction
-
Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.
-
(2007)
Circulation
, vol.116
, pp. 2634-2653
-
-
Thygesen, K.1
Alpert, J.S.2
White, H.D.3
-
56
-
-
67649158245
-
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction
-
Morrow D.A., Wiviott S.D., White H.D., et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009, 119:2758-2764.
-
(2009)
Circulation
, vol.119
, pp. 2758-2764
-
-
Morrow, D.A.1
Wiviott, S.D.2
White, H.D.3
-
57
-
-
68249144596
-
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis
-
O'Donoghue M., Antman E.M., Braunwald E., et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009, 54:678-685.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 678-685
-
-
O'Donoghue, M.1
Antman, E.M.2
Braunwald, E.3
-
58
-
-
77950249728
-
Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients
-
Dauerman H.L., Bhatt D.L., Gretler D.D., et al. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J 2010, 159:508-517.
-
(2010)
Am Heart J
, vol.159
, pp. 508-517
-
-
Dauerman, H.L.1
Bhatt, D.L.2
Gretler, D.D.3
-
59
-
-
74549154500
-
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38
-
Mahoney E.M., Wang K., Arnold S.V., et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010, 121:71-79.
-
(2010)
Circulation
, vol.121
, pp. 71-79
-
-
Mahoney, E.M.1
Wang, K.2
Arnold, S.V.3
-
60
-
-
71849087338
-
Platelet inhibition with cangrelor in patients undergoing PCI
-
Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361:2318-2329.
-
(2009)
N Engl J Med
, vol.361
, pp. 2318-2329
-
-
Harrington, R.A.1
Stone, G.W.2
McNulty, S.3
-
61
-
-
71849119604
-
Intravenous platelet blockade with cangrelor during PCI
-
CHAMPION PLATFORM Investigators
-
Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361:2330-2341. CHAMPION PLATFORM Investigators.
-
(2009)
N Engl J Med
, vol.361
, pp. 2330-2341
-
-
Bhatt, D.L.1
Lincoff, A.M.2
Gibson, C.M.3
-
63
-
-
70649090353
-
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot
-
Berger J.S., Roe M.T., Gibson C.M., et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009, 158:998-1004.
-
(2009)
Am Heart J
, vol.158
, pp. 998-1004
-
-
Berger, J.S.1
Roe, M.T.2
Gibson, C.M.3
-
64
-
-
73149118496
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients
-
Gurbel P.A., Bliden K.P., Antonino M.J., et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 2010, 8:43-53.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 43-53
-
-
Gurbel, P.A.1
Bliden, K.P.2
Antonino, M.J.3
-
66
-
-
77955677366
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
-
Leonardi S., Rao S.V., Harrington R.A., et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010, 160:65-72.
-
(2010)
Am Heart J
, vol.160
, pp. 65-72
-
-
Leonardi, S.1
Rao, S.V.2
Harrington, R.A.3
-
67
-
-
79957630981
-
-
Rao S, for the INNOVATE PCI investigators. A randomized, doubleblind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. Presented at European Society of Cardiology Congress. Stockholm, Sweden, Aug
-
Rao S, for the INNOVATE PCI investigators. A randomized, doubleblind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. Presented at European Society of Cardiology 2010 Congress. Stockholm, Sweden, August 30, 2010.
-
(2010)
-
-
-
68
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
-
(2009)
N Engl J Med
, vol.361
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
69
-
-
77955690680
-
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial
-
TRILOGY ACS Steering Committee
-
Chin C.T., Roe M.T., Fox K.A., et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010, 160:16-22. TRILOGY ACS Steering Committee.
-
(2010)
Am Heart J
, vol.160
, pp. 16-22
-
-
Chin, C.T.1
Roe, M.T.2
Fox, K.A.3
|